Zentalis leads movers in trio of ovarian cancer updates

Among three ovarian cancer readouts spanning different targets, Zentalis’ Phase II data drove the largest single-day stock gain. The week also brought two endometrial cancer updates and several other oncology trial readouts ahead of the upcoming American Association for Cancer Research meeting.

Shares of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) rose 60% on Thursday, adding about $150 million to the company’s market cap, after an interim readout from the Phase II DENALI study showed that the higher dose of its WEE1 inhibitor azenosertib delivered greater efficacy than the lower dose in cyclin E1-positive, platinum-resistant ovarian cancer...